Scientists weaponize immune cells to fight Virus-Linked cancer
NCT ID NCT04139057
Summary
This early-stage trial tested a new cell therapy for head and neck cancers linked to Epstein-Barr virus (EBV). Researchers collected patients' own immune cells (T cells), engineered them to recognize the virus inside cancer cells, and added a component to help them overcome the tumor's defenses. The main goals were to find a safe dose and see if this approach could control the cancer in patients whose disease had returned or spread.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Department of Oncology, Xinqiao Hospital
Chongqing, Chongqing Municipality, 400037, China
Conditions
Explore the condition pages connected to this study.